Mitaprex(Mirtazapine)
Therapeutic Group: Drugs of Nervous System
Presentation
Mitaprex 7.5 mg: Each tablet contains Mirtazapine USP 7.5 mg
Mitaprex 15 mg: Each tablet contains Mirtazapine USP 15 mg
Mitaprex 30 mg: Each tablet contains Mirtazapine USP 30 mg
Description
Mitprex (Mirtazapine) is a tetracyclic antidepressant belongs to piperazine-azepine group of compounds. The mechanism of action is unknown. Studies suggest that Mirtazapine enhances central noradrenergic and serotonergic activity. Mirtazapine acts as an antagonist at central presynaptic alpha-2 adrenergic inhibitory auto receptors and heteroreceptors that result in an increase central noradrenergic and serotonergic activity. Mirtazapine is a potent antagonist of 5 HT2 and 5HT3 receptors.
Indications
Mitaprex (Mirtazapine) is indicated for the treatment of depression.
Dosage & Administration
Adult: Initially, 15 mg daily; may be increased gradually depending on clinical response. Change dose at intervals of at least 1-2 weeks. Usual effective dose: 15-45 mg daily given as single dose, preferably at bedtime, or in 2 divided doses. It can be taken with or without food.
Children: Safety and efficacy not established.
Geriatric: Use with caution.
Side Effects
The most commonly reported adverse effects with mirtazapine are increase in appetite, weight gain, edema, drowsiness or sedation, dizziness, headache etc.
Precautions
Mirtazapine should be used cautiously in patients with epilepsy or history of seizure, history of mania /hypomania, patients with hepatic or renal impairment; cardiac disorders e.g. conduction disturbances, angina pectoris, recent MI. Hypotension, DM, psychoses, history of bipolar disorder. Stop treatment if jaundice develops. Monitor patient for signs of bone marrow depression. Monitor patient for suicidal tendency. Avoid abrupt withdrawal. May impair ability to drive or operate machinery.
Use in Pregnancy & Lactation
Mirtazapine Should not be used during pregnancy and lactation.
Drug Interaction
Mirtazapine potentiates sedative effects with alcohol or benzodiazepines, increased plasma levels with potent CYP3A4 inhibitors (e.g. HIV-protease inhibitors, azole antifungals including ketoconazole, erythromycin, nefazodone), reduced plasma levels with carbamazepine and other inducers of CYP3A4 and increased bioavailability with cimetidine.
Storage
Store at 15 °C-30 °C . Protect from light and moisture.
Commercial Pack
Mitaprex 7.5 mg: Each box contains 3 blister strips of 10 tablets
Mitaprex 15 mg: Each box contains 3 blister strips of 10 tablets
Mitaprex 30 mg: Each box contains 3 blister strips of 10 tablets